Qiagen stock last stood at EUR 39.08 as FDA tests expand

Published on 09/29/2026 at 12:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock gets a new FDA-cleared QIAstat-Dx panel, expanding the menu to 33 pathogen targets and 28 resistance markers. Q2 adjusted EPS was USD 0.62.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0012169213) was last at EUR 39.08 on Xetra on September 29, 2026 at 12:21 p.m. CEST, down 0.59 percent versus the Xetra close of EUR 39.30 on September 28, 2026. The company announced FDA clearance on September 28 for a new QIAstat-Dx bloodstream infection panel, completing its U.S. portfolio, according to Qiagen.

FDA clearance expands the menu

The new QIAstat-Dx BCID GN Plus AMR Panel identifies 13 gram-negative bacterial targets and 18 antibiotic resistance markers. Combined with the previously cleared gram-positive and fungal panel, the U.S. menu now covers 33 pathogen targets and 28 resistance markers, according to Qiagen.

The platform combines sample preparation, multiplex PCR testing and data analysis. Qiagen reported more than 5,200 cumulative QIAstat-Dx placements at the end of 2025, giving the expanded test menu an installed base for additional consumables demand.

Q2 results beat consensus

In the second quarter of 2026, adjusted diluted EPS reached USD 0.62 versus USD 0.60 consensus, while revenue came to USD 535.04 million against USD 527.50 million expected, according to MarketBeat on September 26, 2026. The same report said Qiagen reaffirmed fiscal 2026 adjusted EPS guidance of at least USD 2.43.

The comparison shows the current investment case clearly: revenue was only 0.20 percent higher year over year, but the quarter still exceeded the consensus revenue estimate by USD 7.54 million. Qiagen's adjusted operating margin was 29.40 percent in the quarter, according to Yahoo Finance on September 17, 2026.

Stock remains below its yearly high

Qiagen's market capitalization was EUR 8.1 billion on September 29, 2026, while its 52-week Xetra range stood at EUR 27.56 to EUR 47.60. The EUR 39.08 quote was 18.00 percent below that 52-week high, leaving the regulatory clearance and the next sales response as the measurable checkpoints for the stock.